As previously reported, Craig-Hallum initiated coverage of scPharmaceuticals with a Buy rating and $20 price target. Launched February 2023, Furoscix is in the early stages of launch. The firm says that simply put, this stock needs to be owned as this is a $6.6B opportunity with immense unmet need, incentives for all stakeholders to adopt, and no real competition. Moreover, sNDA filing by the end of Q3 for indication expansion to class IV HF sets up as a catalyst, Craig-Hallum adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals initiated with a Buy at Craig-Hallum
- scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
- scPharmaceuticals reports Q2 EPS (35c), consensus (37c)
- SCPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023
